Goldman Sachs Group Inc Cue Biopharma, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 34,525 shares of CUE stock, worth $34,179. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,525
Previous 18,563
85.99%
Holding current value
$34,179
Previous $14,000
150.0%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding CUE
# of Institutions
57Shares Held
11.9MCall Options Held
22KPut Options Held
1.2K-
Bleichroeder LP New York, NY5MShares$4.95 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$2.04 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$749,1680.0% of portfolio
-
Geode Capital Management, LLC Boston, MA631KShares$624,9680.0% of portfolio
-
Robertson Stephens Wealth Management, LLC San Francisco, CA479KShares$473,7150.02% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $35M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...